Technical Analysis for GKOS - Glaukos Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 138.68 | 0.68% | 0.93 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% |
| Alert | Time |
|---|---|
| Up 1% | about 17 hours ago |
| 60 Minute Opening Range Breakout | about 18 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
| New 52 Week High | about 18 hours ago |
| Fell Below Upper Bollinger Band | about 19 hours ago |
Get a Trading Assistant
- Earnings date: 10/30/2024
Glaukos Corporation Description
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye's anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies, including three pipeline products, namely, the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.
Classification
Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Eye Surgery Medical Technology Ophthalmology Ophthalmic Drainage Glaucoma Implant Vision Blindness Incision Treatment Of Glaucoma Cornea Eye Surgery Intraocular Pressure
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 139.505 |
| 52 Week Low | 59.22 |
| Average Volume | 484,773 |
| 200-Day Moving Average | 110.70 |
| 50-Day Moving Average | 129.61 |
| 20-Day Moving Average | 130.61 |
| 10-Day Moving Average | 132.83 |
| Average True Range | 3.52 |
| RSI (14) | 66.44 |
| ADX | 17.42 |
| +DI | 29.88 |
| -DI | 10.64 |
| Chandelier Exit (Long, 3 ATRs) | 128.95 |
| Chandelier Exit (Short, 3 ATRs) | 135.46 |
| Upper Bollinger Bands | 137.13 |
| Lower Bollinger Band | 124.10 |
| Percent B (%b) | 1.12 |
| BandWidth | 9.97 |
| MACD Line | 2.08 |
| MACD Signal Line | 1.25 |
| MACD Histogram | 0.8238 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 142.93 | ||||
| Resistance 3 (R3) | 142.74 | 141.12 | 142.22 | ||
| Resistance 2 (R2) | 141.12 | 140.04 | 141.22 | 141.99 | |
| Resistance 1 (R1) | 139.90 | 139.37 | 140.51 | 140.10 | 141.75 |
| Pivot Point | 138.29 | 138.29 | 138.59 | 138.38 | 138.29 |
| Support 1 (S1) | 137.07 | 137.20 | 137.68 | 137.26 | 135.61 |
| Support 2 (S2) | 135.45 | 136.53 | 135.55 | 135.37 | |
| Support 3 (S3) | 134.23 | 135.45 | 135.14 | ||
| Support 4 (S4) | 134.43 |
